High Growth Tech Stocks In South Korea For October 2024

The South Korea stock market has experienced fluctuations recently, with the KOSPI index hovering just above 2,580 points following a series of mixed performances influenced by global earnings reports and sector-specific movements. In this environment of alternating gains and losses, identifying high growth tech stocks requires a focus on companies demonstrating resilience and innovation amidst broader market volatility.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
IMLtd	21.80%	111.43%	★★★★★★
Seojin SystemLtd	33.39%	49.13%	★★★★★★
FLITTO	32.60%	106.82%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
NEXON Games	27.44%	69.62%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
Devsisters	29.08%	63.02%	★★★★★★
Park Systems	22.96%	33.25%	★★★★★★
AmosenseLtd	24.04%	71.97%	★★★★★★
UTI	114.97%	134.60%	★★★★★★

Click here to see the full list of 48 stocks from our KRX High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

PharmaResearch (KOSDAQ:A214450)

Simply Wall St Growth Rating: ★★★★★☆

Overview: PharmaResearch Co., Ltd., along with its subsidiaries, functions as a biopharmaceutical company mainly in South Korea, with a market cap of ₩2.42 trillion.

Operations: PharmaResearch Co., Ltd. generates revenue primarily through its pharmaceuticals segment, which accounted for ₩296.59 billion. The company operates in the biopharmaceutical sector, focusing on South Korea.

PharmaResearch's recent strategic moves, including two private placements totaling nearly KRW 200 billion, underscore its aggressive capital acquisition strategy to fuel ongoing projects and potential expansions. This financial influx is pivotal as the company's earnings have surged by 63.2% over the past year, significantly outpacing the Biotech industry's growth of 6.1%. Looking ahead, PharmaResearch is not just resting on its laurels; it is projected to see a revenue increase of 22.3% annually, surpassing South Korea's market average of 10.3%. Moreover, with an anticipated annual profit growth rate of 22.2%, although slightly below the national market expectation of 29.5%, it reflects a robust trajectory in a competitive sector where innovation and rapid adaptation are crucial for sustained growth.

• Click here and access our complete health analysis report to understand the dynamics of PharmaResearch.

• Gain insights into PharmaResearch's historical performance by reviewing our past performance report.

Solus Advanced Materials (KOSE:A336370)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Solus Advanced Materials Co., Ltd. operates by providing materials and solutions across South Korea, Europe, and internationally, with a market capitalization of ₩886.42 billion.

Operations: Solus Advanced Materials Co., Ltd. generates revenue by offering specialized materials and solutions across various regions, including South Korea and Europe. The company's market capitalization stands at ₩886.42 billion, reflecting its significant presence in the industry.

Solus Advanced Materials, a player in South Korea's high-tech landscape, is navigating challenging financial waters with a notable net profit margin drop from 33.5% to 1.6% over the past year. Despite these hurdles, the company's revenue growth outlook remains robust at 27.1% annually, outpacing the Korean market average of 10.3%. This optimism is bolstered by projections of earnings growth at an impressive rate of 87.9% per year, significantly ahead of the market expectation of 29.5%. These figures reflect a resilient strategy aimed at overcoming current profitability challenges and capitalizing on emerging tech trends showcased in recent industry conferences such as the Korea & Global EV/EV Battery Conference.

• Delve into the full analysis health report here for a deeper understanding of Solus Advanced Materials.

• Assess Solus Advanced Materials' past performance with our detailed historical performance reports.

HYBE (KOSE:A352820)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HYBE Co., Ltd. is involved in music production, publishing, and artist development and management, with a market cap of ₩8.03 trillion.

Operations: HYBE generates revenue primarily through its Label and Solution segments, with contributions of ₩1.28 trillion and ₩1.24 trillion, respectively. The Platform segment adds ₩361.12 billion to the company's income stream.

HYBE, a South Korean entertainment giant, is demonstrating robust growth with an expected revenue increase of 13.7% annually, surpassing the local market average of 10.3%. This growth is complemented by a projected annual earnings surge of 42.5%, significantly outpacing broader market expectations. Recently, HYBE has also focused on enhancing shareholder value through strategic share repurchases, buying back 150,000 shares for KRW 26 billion. These financial maneuvers highlight HYBE's aggressive strategy to capitalize on expanding global entertainment demands while reinforcing its market position through sound fiscal management and investor-friendly actions.

• Dive into the specifics of HYBE here with our thorough health report.

• Explore historical data to track HYBE's performance over time in our Past section.

Where To Now?

• Navigate through the entire inventory of 48 KRX High Growth Tech and AI Stocks here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com